Clinical Studies and Translational Research for Novel Vaccines Against Emerging Viruses

Keralty is an international integrated health group delivering care to 9 million patients with 27,000 professionals across Colombia, Peru, Mexico, and the United States. The organisation combines healthcare delivery, diagnostics, research, and digital health within an integrated model and has prior experience in H2020 and Horizon Europe projects, contributing clinical expertise, cohorts, and real-world implementation settings.

Keralty is well positioned to contribute to HORIZON-HLTH-2026-01-DISEASE-04, supporting the development of novel prophylactic and therapeutic vaccines for viral pathogens with epidemic potential. Keralty can participate as a partner for clinical studies, offering:

• Access to diverse populations for first-in-human and early clinical safety studies

• Experience in infectious disease management, immunisation programmes, and long-term follow-up

• Capacity to integrate sex, age, ethnicity, and socio-behavioural factors into clinical research and data analysis

• Real-world healthcare settings aligned with regulatory and ethical requirements

A major asset is Keralty’s network of more than 70 laboratories, staffed by highly qualified professionals and equipped with cutting-edge technologies in areas such as genomics, molecular biology, immunology, and infectious diseases. This infrastructure supports advanced in-vitro and translational research, biomarker and immune response analysis, pathogen characterisation, and diagnostics relevant to vaccine development and evaluation.

In addition, BioKeralty Research Institute, part of Keralty Group’s R&D&I division, can join consortia as a complementary research partner. BioKeralty brings expertise in translational and clinical research, personalised medicine, digital health, and data analytics, supporting study design, data harmonisation, FAIR data management, and alignment with European research infrastructures. BioKeralty also has strong capabilities in communication, dissemination, and exploitation of results, contributing to regulatory engagement, stakeholder communication, and impact maximisation.

Together, Keralty and BioKeralty offer a strong combination of clinical trial capacity, advanced laboratory infrastructure, translational research expertise, and experience in EU-funded collaborative projects. They are keen to collaborate with academic institutions, biotech companies, SMEs, and public partners in consortia advancing vaccine development for emerging and re-emerging viral threats, strengthening preparedness and response to future epidemics and pandemics.